Oricell Therapeutics secured more than $110 million in a pre-IPO round to expand its global footprint and move its lead GPC3-targeted autologous CAR-T therapy toward registrational trials. The company frames Ori-C101 as a liver-cancer program aimed at advanced hepatocellular carcinoma, a setting where solid-tumor targeting remains difficult. Oricell’s funding round builds on prior investor support and is designed to accelerate clinical development and strengthen technology capabilities. The company previously completed investigator-initiated testing and a registrational phase 1 trial, and it expects pivotal studies to follow as it works toward a potential global submission pathway. The company also highlighted a broader portfolio, including additional solid-tumor and blood-cancer programs and in vivo CAR-T strategies, which aim to address the logistical and immunologic barriers that have limited many solid-tumor CAR-T approaches. The financing arrives as cell therapy investors seek scalable platforms that can deliver efficacy in harder-to-treat tumor microenvironments, particularly where antigen heterogeneity and immune suppression complicate single-target approaches.